Last reviewed · How we verify

Dexlansoprazole MR QD

Takeda · Phase 3 active Small molecule

Dexlansoprazole MR QD is a Proton pump inhibitor (PPI) Small molecule drug developed by Takeda. It is currently in Phase 3 development for Gastroesophageal reflux disease (GERD), Healing of erosive esophagitis, Maintenance of healed erosive esophagitis. Also known as: TAK-390, T-168390, TAK-390MR, Kapidex.

Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in parietal cells.

Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in parietal cells. Used for Gastroesophageal reflux disease (GERD), Healing of erosive esophagitis, Maintenance of healed erosive esophagitis.

At a glance

Generic nameDexlansoprazole MR QD
Also known asTAK-390, T-168390, TAK-390MR, Kapidex, Dexilant
SponsorTakeda
Drug classProton pump inhibitor (PPI)
TargetH+/K+-ATPase
ModalitySmall molecule
Therapeutic areaGastroenterology
PhasePhase 3

Mechanism of action

Dexlansoprazole is the active R-enantiomer of lansoprazole, a proton pump inhibitor (PPI). It binds to and inactivates the hydrogen-potassium adenosine triphosphatase (H+/K+-ATPase) pump on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. The modified-release (MR) formulation provides dual-peak plasma concentrations to maintain acid suppression throughout the day with once-daily dosing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dexlansoprazole MR QD

What is Dexlansoprazole MR QD?

Dexlansoprazole MR QD is a Proton pump inhibitor (PPI) drug developed by Takeda, indicated for Gastroesophageal reflux disease (GERD), Healing of erosive esophagitis, Maintenance of healed erosive esophagitis.

How does Dexlansoprazole MR QD work?

Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in parietal cells.

What is Dexlansoprazole MR QD used for?

Dexlansoprazole MR QD is indicated for Gastroesophageal reflux disease (GERD), Healing of erosive esophagitis, Maintenance of healed erosive esophagitis.

Who makes Dexlansoprazole MR QD?

Dexlansoprazole MR QD is developed by Takeda (see full Takeda pipeline at /company/takeda).

Is Dexlansoprazole MR QD also known as anything else?

Dexlansoprazole MR QD is also known as TAK-390, T-168390, TAK-390MR, Kapidex, Dexilant.

What drug class is Dexlansoprazole MR QD in?

Dexlansoprazole MR QD belongs to the Proton pump inhibitor (PPI) class. See all Proton pump inhibitor (PPI) drugs at /class/proton-pump-inhibitor-ppi.

What development phase is Dexlansoprazole MR QD in?

Dexlansoprazole MR QD is in Phase 3.

What are the side effects of Dexlansoprazole MR QD?

Common side effects of Dexlansoprazole MR QD include Headache, Diarrhea, Abdominal pain, Nausea, Upper respiratory tract infection.

What does Dexlansoprazole MR QD target?

Dexlansoprazole MR QD targets H+/K+-ATPase and is a Proton pump inhibitor (PPI).

Related